1. Home
  2. AUPH

AUPH

Aurinia Pharmaceuticals Inc

Logo Aurinia Pharmaceuticals Inc

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-18-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.

Founded: N/A Country:
Canada
Canada
Employees: N/A City: EDMONTON
Market Cap: 730.3M IPO Year: 1999
Target Price: $10.33 AVG Volume (30 days): 2.1M
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.54 EPS Growth: N/A
52 Week Low/High: $4.85 - $12.43 Next Earning Date: 05-02-2024
Revenue: $175,513,000 Revenue Growth: 30.95%
Revenue Growth (this year): 30.32% Revenue Growth (next year): 28.82%

Share on Social Networks: